Alignment Healthcare, Inc. (ALHC)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below the required floor of 3) — the upstream qualitative screen's confirmed material litigation overhang and sharply deteriorating in-window sentiment/tape hard-block any new long — and the overnight-gap gate fires (max overnight gap 5.03% on the Sep 15 regular open vs prior regular close exceeds the 5% ceiling), so the protective stop cannot cover off-hours repricing. Both entry types were considered and rejected on the chart itself: a pullback/oversold limit is countertrend (price 8.70 below the SMA50 15.34 with MACD -1.36 < 0, and below a declining SMA200 without a momentum reclaim), and no breakout stop qualifies on a new 52-week low with no settled consolidation floor to anchor a trigger.
Company overview
Alignment Healthcare, Inc. is a Medicare Advantage provider leveraging technology to deliver personalized medical services across the United States. The company operates its own Medicare Advantage programs in California, North Carolina, and Nevada, and provides healthcare services for other Medicare Advantage plans. Established in 2013, it is based in Orange, California.
Fundamental
fairThe company shows strong revenue growth and liquidity but faces thin margins and regulatory risks.
Score 3/5 (Mixed but improving): SEC filings show strong Medicare Advantage membership/revenue growth and a turn to GAAP profitability in 1H 2026 with solid liquidity (cash ~$694M, undrawn revolver). Valuation looks cheap on sales (EV/Sales ~0.53x) but earnings power is still thin (TTM net margin ~0.9%, EV/EBITDA ~27.8x, P/E ~67.9x) and the business remains exposed to CMS reimbursement/regulatory changes and competitive pressure.
Sentiment
weakSentiment is negatively impacted by litigation overhangs and insider sales, with no positive catalysts.
ALHC enters the window under two unresolved, media-confirmed overhangs — the CMS star-ratings recalculation litigation and a whistleblower accounting-fraud suit — and an in-window tape that deteriorated sharply (star-ratings silence at a Baird event triggered a double-digit retreat around Sep 15–16, alongside C-level insider sales and a fresh law-firm fraud-investigation PR wave). The news sentiment delta is determinate and essentially flat at mildly negative on both windows (baseline ≈ −0.06, scoring ≈ −0.01), Red-Flag Screen shows no severe flags, and moderate red-flag cap applies (material litigation; deteriorating sentiment with no offsetting bullish catalyst).
Technical
weakThe stock is in a strong downtrend with deeply oversold conditions suggesting only a potential technical bounce.
Broken structure: price 8.70 sits below every major moving average (SMA20 12.72, SMA50 15.34, SMA200 18.64, EMA9 11.18, EMA21 12.54, WMA21 12.21) after a ~35% three-session collapse (12.94 close on 09-14 to 8.70 on 09-17) on record distribution volume (~25M shares/day vs ~5M prior average). Momentum is decisively negative: MACD line -1.36 vs signal -1.02 with histogram -0.34 still expanding downward, ADX 27.75 confirming a strong downtrend (direction-agnostic, but price below all MAs makes it a strong DOWN trend). The only constructive element is depth: RSI 17.50 and Williams %R -92.42 are deeply oversold, which supports a bounce-only profile, not a reversal setup. ATR14 0.95 = 10.9% of price reflects extreme volatility. Chart quality score 2 (bounce-only at best); no tradable setup regardless, and the action is hard-blocked by the qualitative floor (qualitativeScore 2 < 3) plus the overnight-gap gate (max 5.03% > 5%).
You’re looking at 2026-09-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.